ERBB2 and triple-negative breast carcinoma: Two hundred and fifty-six patients (87.1%) had invasive ductal carcinoma, 14.3% had triple-negative breast cancer, >60% were HR positive, 16% were HER2 positive, and 90% received anthracycline combined with taxane-based chemotherapy.